Recombinant IL21 (Avizakimab Biosimilar) anticorps
Aperçu rapide pour Recombinant IL21 (Avizakimab Biosimilar) anticorps (ABIN7581498)
Antigène
Type d'anticorp
Reactivité
Hôte
Clonalité
Conjugué
Application
-
-
Expression System
- CHO Cells
-
Fonction
- Anti-IL-21 Reference Antibody (avizakimab)
-
Séquence
- QVQLVQSGAE VKKPGASVKV SCKASGYTFT DYWMHWVRQA PGQGLEWMGT IDPSDQYTIY SQNFKGRVTM TRDTSTSTVY MELSSLRSED TAVYYCARYG FAMDYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKRVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL YITREPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK,DIQLTQSPSS LSASVGDRVT ITCRASQDIS NFLNWYQQKP GKAVKLLIYY TSRLHSGVPS RFSGSGSGTD YTLTISSLQP EDFATYYCQQ GHTLPRTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
-
Attributs du produit
- Anti-IL-21 Reference Antibody (avizakimab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
Pureté
- >95 %
-
Isotype
- IgG1
-
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Commentaires
-
Therapeutic Agents by Target and Mechanism: IL-21 inhibitors
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Stock
- 4 °C,-80 °C
-
Stockage commentaire
- +4°C,-80°C
-
-
- IL21 (Avizakimab Biosimilar)
-
Autre désignation
- IL-21 (Avizakimab Biosimilar)
-
Classe de substances
- Biosimilar
-
Poids moléculaire
- 145.5 kDa
-
UniProt
- Q9HBE4
Antigène
-